For example, LMNA mutations are known to predispose individuals to VAs and SCD, regardless of LV function [107], while patients with PLN and RBM20 mutations should allow for more intensive follow-up and the timely provision of advanced HF therapies [75]. The gene discussed is PLN; the disease is Schnyder corneal dystrophy.